MRx0518 for Bladder Cancer (AVENU Trial)

"Our team at Power placed Avelumab 20 mg/mL Intravenous Solution (IV) on the safety scale with a 2 rating, as phase two trials have generated some evidence of its security, yet not any that corroborates efficacy."

"Research surrounding Avelumab 20 mg/mL Intravenous Solution (IV) dates back to 2014 when it was sponsored by EMD Serono Research & Development Institute, Inc. In that year the inaugural trial concluded with 204 participants and earned its Phase 2 approval. Today, this drug is being tested in a total of 112 trials spanning 1024 cities across 52 nations."

"Currently, 112 clinical trials are being conducted on Avelumab 20 mg/mL Intravenous Solution (IV), 10 of which have progressed to Phase 3. Barcelona, South dakota is the main hub for these studies; nonetheless, there are 3685 sites around the world running tests with this medication."

"Unfortunately, this specific trial is not currently in search of participants. It was posted on March 1st 2022 and last revised July 5th 2022. However, there are 2515 trials related to transitional cell carcinoma presently open for recruitment as well as 112 clinical studies involving Avelumab 20 mg/mL Intravenous Solution (IV)."

"This clinical trial aims to evaluate the safety of MRx0518 and Avelumab combination treatment over a 6-month period. Secondary objectives include measuring objective progressive disease (PD) duration, progression-free survival (PFS), as well as time to response from first dose until confirmed tumor response."

"According to clinicaltrials.gov, recruitment for this study has been suspended since July 5th 2022; however, there are still 2,627 other medical trials actively recruiting patients at the current moment."